Power Law company profile

CureVac

Biotech & Life Sciences · Tübingen, Germany · Founded 2000 · IPO 2020 Unicorn

Develops drugs that allow the human body to fight various diseases

Valuation

$599M

Market cap · Jan/2026

Revenue

$589M

Latest reported FY

EBITDA

$230M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

10 investors on CureVac's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

DH Capital

Series B+ 9 investors entered at this stage

GSK

KfW

Bill & Melinda Gates Foundation

Baillie Gifford

University of Tübingen

dievini Hopp Biotech holding

Baden-Württembergische Versorgungsanstalt für Ärzte

Qatar Investment Authority

LBBW Venture Capital

Global footprint

Where CureVac has talent and traffic

AI talent share

0.8% of workforce is AI talent
(5 of 640 staff)

Core AI20.31%

Other AI30.47%

Non-AI workforce63599.22%

Workforce by country

12 countries with
team presence

🇩🇪 Germany91%

🇧🇪 Belgium2.5%

🇺🇸 United States1.8%

🇳🇱 Netherlands1%

🇨🇭 Switzerland0.9%

Top 5 of 12 shown

Web traffic by country

10K monthly visits
across markets

🇦🇺 Australia40%

🇩🇪 Germany36%

🇺🇸 United States16%

🇮🇳 India6%

🇳🇱 Netherlands3%

Top 5 markets shown

Patent intelligence

$159M patent portfolio · 115 active families

Estimated portfolio value

$159M

26.5% of market cap · 4.9× smaller than top peer BioNTech ($780M)

115 active patent families

Where CureVac innovates Molecular biologyRNABioinformaticsIn vitro transcriptionBiochemistry

Where CureVac concentrates vs peers

Each axis is a top-10 topic across CureVac and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about CureVac

An AI-synthesized read of the highest-engagement posts about CureVac on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CureVac on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles